Taken together these results, we believe that the simultaneous induction of STEAP- and EZH2-specific CD4 and CD8 T-cell responses would be more effective in achieving anti-tumor effects than the separate induction of CD4, or CD8 T-cell responses. The gene discussed is CD4; the disease is neoplasm.